CompletedNCT01025700
Nabilone for cannabis craving and addiction
About this title
Read the official source — NCT01025700Medication studyAges 19–65Canada
Understand this study
Who was this study for?
Listed age limits: 19 years to 65 years.
- Listed locations
- VancouverSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateJune 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 35
- Sponsor
- University of British Columbia
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Canada
- Age range
- From 19 Years to 65 Years
- Official registry ID
- NCT01025700
- Official title
Show the full official title
A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Vancouver
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of British Columbia, a university.
Did this study involve medication?
Yes. The study involved medication, including Cesemat.
Who was this study for?
Listed age limits: 19 years to 65 years.
